Quantitation of monoclonal antibody infliximab in human plasma by LC-MS/MS using Fab-selective limited proteolysis nSMOL technology

Infliximab, known commercially as Remicade, is a chimeric IgG1 kappa monoclonal antibody (mAb) that targets tumor necrosis factor-alpha (TNF).
In studies conducted, a significant number of patients (30-40%) who did not respond to anti-TNF treatment were identified.
Current methods for monitoring infliximab are almost exclusively based on immunological tests.

In this study, the amount of infliximab was more selectively determined by LC-MS / MS using nSMOL proteolysis targeting the Fab CDR region.